Catecholestrogens excretion in smoking and non-smoking postmenopausal women receiving estrogen replacement therapy

Journal of Steroid Biochemistry and Molecular Biology

Volumn 72, Issue 3-4, 2000, Pages 143-147

  Berstein, Lev M ^a   Tsyrlina, Evgenia V ^a   Kolesnik, Olga S ^a   Gamajunova, Vera B ^a   Adlercreutz, Herman ^b  

^a N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Catecholestrogens; Estrogen replacement therapy; Estrogens; Hormonal carcinogenesis; Smoking

Indexed keywords

CATECHOL ESTROGEN; ESTRADIOL VALERATE; ESTROGEN;

ADULT; ARTICLE; BREAST CARCINOGENESIS; CANCER RISK; CARCINOGENESIS; CATECHOLAMINE RELEASE; CLINICAL ARTICLE; CONTROLLED STUDY; ESTROGEN DEFICIENCY; ESTROGEN METABOLISM; ESTROGEN THERAPY; FEMALE; GAS CHROMATOGRAPHY; GENOTOXICITY; HORMONAL CARCINOGENESIS; HUMAN; MASS SPECTROMETRY; POSTMENOPAUSE; SMOKING; URINALYSIS; URINARY EXCRETION;

BREAST NEOPLASMS; DNA DAMAGE; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CATECHOL; FEMALE; HUMANS; MENOPAUSE; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; RISK FACTORS; SMOKING;

EID: 0034164017     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(00)00038-8     Document Type: Article

References (27)

1. Feigelson H.S., Henderson B.E. Estrogens and breast cancer. Carcinogenesis. 17:1996;2279-2284.
2. Santen R.J. Estrogen synthesis inhibitors for breast cancer: An introductory overview. Endocrine-Related Cancer. 3:1996;1-8.
3. Gurpide E. Endometrial cancer: biochemical and clinical correlates. J. Natl. Cancer Inst. 83:1991;405-416.
4. Key T.J.A., Pike M.C. The dose-effect relationship between "unopposed " oestrogens and endometrial mitotic rate. Its central role in explaining and predicting endometrial cancer risk. Brit. J. Cancer. 57:1988;205-212.
5. Liehr J.G., Ricci M.J. 4-hydroxylation of estrogens as marker of human mammary tumors. Proc. Natl. Acad. Sci. 93:1996;3294-3296.
6. Cavalieri E.L., Stack D.E., Devanesan P.D., et al. Molecular origin of cancer: catechol estrogen-3, 4-quinones as endogenous tumor initiators. Proc. Natl. Acad. Sci. 94:1997;10937-10942.
7. Adlercreutz H., Gorbach S.L., Goldin B.R., et al. Estrogen metabolism and excretion in Oriental and Caucasian women. J. Natl. Cancer Inst. 86:1994;1076-1082.
8. Zhu B.T., Conney A.H. Functional role of estrogen metabolism in target cells: review and perspectives. Carcinogenesis. 19:1998;1-27.
9. Collaborative Group on Hormonal Factors in Breast Cancer, Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52705 women with breast cancer and 108411 women without breast cancer. Lancet 350 (1997) 1047-1059.
10. Berstein L.M. Hormonal carcinogenesis and smoking. Cancer J. 9:1996;106.
11. Berstein L.M., Tsyrlina E.V., Krjukova O.G., Dzhumasultanova S.V. Influence of tobacco smoke on DNA unwinding and uterotropic effect of estrogens in rats. Cancer Letters. 127:1998;95-98.
12. Yager J.D., Liehr J.G. Molecular mechanisms of estrogen carcinogenesis. Annu. Rev. Pharmacol. Toxicol. 36:1996;203-232.
13. Michnovicz J.J., Hershcopf R.J., Nagamura H. Increased 2-hydroxylation of estradiol as a possible mechanism for the anti-estrogenic effect of cigarette smoking. New Engl. J. Med. 315:1986;1305-1309.
14. Fotsis T., Adlercreutz H. The multicomponent analysis of estrogens in urine by ion exchange chromatography and GC-MS-I. Quantitation of estrogens after initial hydrolysis of conjugates. J. Steroid. Biochem. 28:1987;203-213.
15. Baron J.A., Greenberg E.R. Cigarette smoking and neoplasms of the female reproductive tract and breast. Seminars Reproductive Endocrinol. 7:1989;335-343.
16. Brunet J.S., Ghadirian P., Rebbeck T.R., et al. Effect of smoking on breast cancer in carriers of mutant BRCA1 or BRCA2 genes. J. Natl. Cancer Inst. 90:1998;761-766.
17. Berstein L.M. Oncoendocrinology of Smoking. 1995;Nauka, Moscow.
18. Key T., Pike M.C., Brown J.B., et al. Cigarette smoking and urinary oestrogen excretion in premenopausal and post-menopausal women. Brit. J. Cancer. 74:1996;1313-1316.
19. Jensen J. Smoking and postmenopausal hormone replacement therapy. Brit. J. Clin. Pract. 86:1996;6-8. Symp. Suppl.
20. Telang N.P., Suto A., Wong G.Y., et al. Induction by estrogen metabolite 16α-hydroxyestrone of genotoxic damage and aberrant proliferation in mouse mammary epithelial cells. J. Natl. Cancer Inst. 84:1992;634-643.
21. Adlercreutz H., Fotsis T., Hockerstedt K., et al. Diet and urinary estrogen profile in premenopausal omnivorous and vegetarian women and in premenopausal women with breast cancer. J. Steroid. Biochem. 34:1989;527-530.
22. Daniell H.W. More advanced-stage tumors among smokers with endometrial cancer. Amer. J. Clin. Pathol. 100:1993;439-443.
23. Daniell H.W., Tam E., Filice A. Larger axillary metastases in obese women and smokers with breast cancer - an influence by host factors on early tumor behavior. Breast Cancer Res. Treatment. 25:1993;193-201.
24. Fotsis T., Zang Y., Pepper M.S., et al. The endogenous oestrogen metabolite 2-methoxyestradiol inhibits angiogenesis and suppresses tumor growth. Nature (London). 368:1994;237-239.
25. Klauber N., Parangi S., Flynn E., et al. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res. 57:1997;81-86.
26. Miller W.R. Estrogen and Breast Cancer. 1996;R.G. Landes Comp, Austin.
27. Burger H. Clinical indications for hormone replacement therapy. Obsterical Gynecol. Surveys. 53:1998;S10-S13.